Protein analysis

Protein

Innovative Technology Support Group for Life Science and Drug Discovery

PC1-3

PC1-3 : Full-length Amino acid Sequencing

Test Introduction

PC1-3 is a test category that defines a total amino acid sequencing of target protein’s total amino acid through LC-MS/MS analysis methods. It has been used to define the difference of finalized total sequencing between theoretical protein sequence and target protein’s sequencing by comparing and analyzing two protein sequence. Also, it is possible to confirm the sequence of finalized total protein information by using protein database and peptide mapping methods using a variety of protease If there is no reference about the sequencing of a target protein.

Sample

  • Biosimilar
  • Biobetter
  • Antibody
  • Antibody-drug conjugates
  • Recombinant protein drug
  • Toxin
  • vaccine

Analysis Process

  • Protease Digestion
  • LC-MS/MS, MRM
  • Peptide Map De-novo sequencing
  • Determination of amino-acid sequence

Analysis Result

De-novo sequencing

Scroll to the left and right to reveal the contents.
Frag# Res# Charge m/z RT(min) Sequence
T1 1-24 4 699.34 49.7 TAGYFFGGCYQPCSSTMFEK
T2 25-31 3 652.35 33.5 APTAPPK
T3 32-42 2 587.35 22.6 VTSPNITVTLK
T5 44-54 2 605.34 34.1 CTQEASTPWK
T4-5 43-54 2 672.38 32.9 KFPLDTLIPDGK
T5-6 44-55 2 686.39 31.0 FPLDTLIPDGKR
T7 56-61 1 789.43 16.7 IIWDSR
T9 63-72 2 557.80 24.4 GFIISNATYK
T8-9 62-72 2 621.84 21.1 KGFIISNATYK
T10 73-89 3 640.32 31.6 EIGLLTCEATVNGHLYK
T11 90-96 2 452.74 3.4 TNYLTHR
T12 97-119 3 812.77 45.0 QTNTIIDVVLSPSHGIELSVGEK
T13(G) 120-127 2 474.26 14.0 LVLNCTAR
T14 128-144 2 999.98 41.3 TELNVGIDFNWEYPSSK
T14-16 128-149 3 886.44 31.7 TELNVGIDFNWEYPSSKHQHKK
T17 150-153 1 501.31 1.9 LVNR
T18-19 154-164 2 612.30 6.8 DLKTQSGSEMK
T21 166-177 2 661.87 30.6 FLSTLTIDGVTR
T20-21 165-177 2 725.92 29.2 KFLSTLTIDGVTR
T19-21 157-177 4 575.56 39.0 TQSGSEMKKFLSTLTIDGVTR
T22 178-194 2 895.41 24.2 SDQGLYTCAASSGLMTK
T23-24 195-201 2 426.74 5.1 RTNSSK